SAN CARLOS, CA --(Marketwired - November 23, 2016) - Lion Biotechnologies, Inc. (
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/ . A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies, Inc.
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com .
Investor Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media Contact: Alex Ferrara inVentivHealth Public Relations 212-849-9487 Alexandra.Ferrara@inventivhealth.com